Product Description: Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50./[2]Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54./[3]Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.
CAS Number: 174722-31-7
Molecular Weight: 144544.44
Compound Purity: 99.00
Research Area: Cancer; Inflammation/Immunology
Solubility: 10 mM in H2O
Target: CD20
English
Deutsch
